[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100293612":3},{"organization":4,"armGroups":7,"interventions":26,"overallOfficials":34,"centralContacts":39,"locations":45,"responsibleParty":61,"collaborators":43,"id":65,"slug":66,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":43,"eligibilityCriteria":71,"healthyVolunteers":67,"sex":72,"minAge":73,"maxAge":43,"enrollmentInfo":74,"targetDuration":43,"studyType":77,"phases":78,"briefSummary":80,"conditions":81,"keywords":83,"overallStatus":47,"whyStopped":43,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},{"fullName":5,"class":6},"University of California, San Diego","OTHER",[8,14,18,22],{"label":9,"type":10,"description":11,"interventionNames":12},"Nonspecific allograft dysfunction","EXPERIMENTAL","Patients with nonspecific allograft dysfunction will undergo stress cardiac MRI with regadenoson in addition to performing late gadolinium enhancement and obtaining mean segmental T1 values of the heart. Peripheral blood and endomycardial biopsies will also be obtained for single cell RNAseq analyses.",[13],"Drug: Regadenoson",{"label":15,"type":10,"description":16,"interventionNames":17},"Normal graft function","Patients with normal graft function will undergo stress cardiac MRI with regadenoson in addition to performing late gadolinium enhancement and obtaining mean segmental T1 values of the heart. Peripheral blood and endomycardial biopsies will also be obtained for single cell RNAseq analyses.",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Cardiac allograft vasculopathy","Patients with allograft dysfunction from known cardiac allograft dysfunction will undergo stress cardiac MRI with regadenoson in addition to performing late gadolinium enhancement and obtaining mean segmental T1 values of the heart. Peripheral blood and endomycardial biopsies will also be obtained for single cell RNAseq analyses.",[13],{"label":23,"type":10,"description":24,"interventionNames":25},"ACR\u002FAMR","Patients with allograft dysfunction from prior episodes of acute cellular or antibody mediated rejection will undergo stress cardiac MRI with regadenoson in addition to performing late gadolinium enhancement and obtaining mean segmental T1 values of the heart. Peripheral blood and endomycardial biopsies will also be obtained for single cell RNAseq analyses.",[13],[27],{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"DRUG","Regadenoson","For use in stress myocardial perfusion imaging.",[23,19,9,15],[33],"Lexiscan",[35],{"name":36,"affiliation":37,"role":38},"Paul Kim, MD","UC San Diego","PRINCIPAL_INVESTIGATOR",[40],{"name":36,"role":41,"phone":42,"phoneExt":43,"email":44},"CONTACT","8582460638",null,"pjk017@ucsd.edu",[46],{"facility":37,"status":47,"city":48,"state":49,"zip":50,"country":51,"countryCode":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":59},"RECRUITING","La Jolla","California","92037","United States","US",{"type":54,"coordinates":55},"Point",[56,57],-117.2742,32.84727,{"lat":57,"lon":56},[60],{"name":36,"role":41,"phone":42,"phoneExt":43,"email":44},{"type":62,"investigatorFullName":63,"investigatorTitle":64,"investigatorAffiliation":5,"oldNameTitle":43,"oldOrganization":43},"SPONSOR_INVESTIGATOR","Paul Kim","Assistant Professor","100293612","phase-4-allograft-dysfunction-in-heart-transplant-100293612",false,"NCT03102125","Allograft Dysfunction in Heart Transplant","Defining Mechanisms for Cardiac Allograft Dysfunction to Improve Allograft Longevity and Survival in Heart-Transplant Patients","Inclusion Criteria:\n\n* Age greater than or equal to 18 years old.\n* At least three months status post heart transplantation.\n\nExclusion Criteria:\n\n* Biopsy proven acute rejection episode in the past 3 months.\n* Patients with symptoms or signs of acute myocardial ischemia or recent acute coronary syndrome in the past 3 months.\n* Uncontrolled obstructive ventilatory disease including asthma and COPD.\n* History of generalized tonic-clonic seizures.\n* Second or third degree AV nodal block.\n* Sinus node dysfunction.\n* Contraindications to MRI including cardiovascular implantable electronic devices.\n* Renal dysfunction with an estimated GFR less than 30 mL\u002Fmin\u002F1.73m2.\n* Prior adverse reaction to either regadenoson or gadolinium contrast. Prior adverse reaction to adenosine or dipyridamole will be assessed on a case-by-case basis.\n* Systolic blood pressure greater than 180 or less than 85 mmHg.\n* Diastolic blood pressure greater than 120 or less than 40 mmHg.\n* Resting heart rate greater than 120 or less than 45 beats per minute. - Severe claustrophobia.","ALL","18 Years",{"count":75,"type":76},376,"ESTIMATED","INTERVENTIONAL",[79],"PHASE4","The investigators will evaluate for early evidence of cardiac allograft dysfunction by cardiac MRI and single cell sequencing to determine underlying molecular and macroscopic causes.",[82],"Heart Transplant Failure and Rejection",[84,85,86],"heart transplant","acute graft rejection","chronic graft rejection","2026-04-27",{"date":89,"type":90},"2026-05-01","ACTUAL",{"date":92,"type":90},"2019-10-01",{"date":94,"type":76},"2027-01-02",{"name":63,"class":6},1]